I. MODIFIED AGREEMENTS | |||
Company* (Country; Symbol) | Company* (Country; Symbol) | Change from original agreement | Terms/Details (Date) |
Actelion Ltd. (Switzerland; SWX:ATLN) |
Celltech Group plc (UK; NYSE:CLL) |
Modified deal covering Zavesca, which is approved for Type I Gaucher's disease |
Actelion has full rights and responsibilities for the drug in glycolipid disorders; Celltech previously could have re-acquired rights; Celltech manufactures the product and gets royalties on sales (6/16) |
Array BioPharma Inc. (ARRY) |
Trimeris Inc. (TRMS) |
They renewed 2001 deal for the discovery of small- olecule entry inhibitors for HIV |
Array is entitled to research funding as well as potential milestones and royalties; terms are similar to those in the original deal (6/3) |
Biolex Inc.* |
Centocor Inc. (unit of Johnson & Johnson) |
Expanded deal to include limited scale-up of the first of three Centocor proteins expressed in Biolex's LEX System |
Centocor also added a fourth protein to the deal, terms of which were not disclosed (6/4) |
Cepheid Inc. (CPHD) |
Applied Biosystems Group (NYSE:ABI) and Celera Diagnostics (venture of ABG and Celera Genomics Group; NYSE:CRA) |
Nonexclusive license deal on real-time thermal cycler instruments for research, diagnostic and other uses |
Expanded deal adding diagnostics to Cepheid's rights to use thermal cyclers under Applera's patent rights; hepatitis C and HIV are not included in the deal (6/23) |
OSI Pharmacueticals Inc. (OSIP) |
Genentech Inc. (NYSE:DNA) |
Amended January 2001 deal to further clarify roles for development and sales of the cancer drug Tarceva in the U.S. |
OSI will provide at least 25% of the sales force; they will share post-launch development responsibilities; OSI is responsible for the NDA filing and is responsible for manufacturing for the U.S. market (6/16) |
Nanobac Life Sciences Inc. (OTC BB:NNBP) |
Pegasus Worldwide Inc.* |
Nanobac exercised its right to take over marketing of its nanobiotic regimen |
Details were not disclosed; nanobacteria are associated with pathologic calcification in various diseases (6/18) |
II. TERMINATED AGREEMENTS | |||
Amrad Corp. (Australia; ASX:AML) |
Serono SA (Switzerland; NYSE:SRA) |
Serono returned rights to emfilermin, a product for increasing pregnancy rates, after a failed trial |
Amrad does not expect to further develop the leukemia inhibitory factor compound as an infertility treatment (6/2) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange. | |||
